30 closest matches · ranked by relevance
Secondary Hyperparathyroidism · Chronic Renal Insufficiency
Primary: Reduction in Mean iPTH of ≥ 30% During the Efficacy Assessment Phase — 15; 5 Participants — p=0.006
Hyperparathyroidism · Chronic Kidney Disease
Primary: Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate — -11.7; 16.4 percentage of baseline [PTH]
Secondary Hyperparathyroidism
Primary: Percent Change From Baseline in Parathyroid Hormone (PTH) During the Efficacy Period — -53.6; -55.6; -50.8 percent change
Secondary Hyperparathyroidism
Primary: Percent Change From Baseline in Mean Pre-hemodialysis Parathyroid Hormone (PTH) During the Efficacy Assessment Phase — 0.3; -19.4; 28.5; -49.4 percent change — p=<0.0001
End Stage Renal Disease
Primary: Number of Participants With Mean PTH ≤ 300 pg/mL — 262; 41 Participants — p=<0.001
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Confirmed Hypercalcemia — 3; 1 participants — p=0.36
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
Hyperparathyroidism · Disorders of Parathyroid Gland
Primary: Rate of Achieving the Target on Blood Intact Parathyroid Hormone Level According to Kidney Development Improvement Global Outcome (KDIGO) Guidelines. — 30.8; 57.1; 90.0…
Secondary Hyperparathyroidism · Renal Insufficiency, Chronic · Parathyroid Hormone
Primary: The Percentage of Patients Reaching at Least a 30% Reduction in PTH and/or Values in Range 150-300 pg/mL — 96.6 Percentage of participants
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events — 768; 436; 287; 4 participants
Hyperparathyroidism, Secondary
Primary: Percent Change From Baseline in Mean PTH During Efficacy Assessment Phase (EAP) — -7; -12.1 Percent change — p=0.346
Renal Osteodystrophy
Primary: Percent Reduction in PTH — 27; 10 % change in PTH baseline to 3 months
Chronic Allograft Nephropathy · Chronic Kidney Disease · Chronic Renal Failure
Primary: Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) — 3.5; 78.9 percentage…
Secondary Hyperparathyroidism · Hemodialysis
Primary: The Percentage of Participants With a >=50% Reduction in Intact Parathyroid Hormone (iPTH) From Baseline Compared to the Average iPTH Obtained in the Last 3 Weeks…
Secondary Hyperparathyroidism
Primary: Change From Baseline to End of Study in Bone Formation Rate (BFR) — -488 μm^2/mm^2/day
Secondary Hyperparathyroidism
Primary: The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours — 40.6; 46.2; 39.8; 58.8 pg/ml — p=0.1
Secondary Hyperparathyroidism · Dialysis
Primary: Proportion of Subjects Who Achieve at Least a 50% Reduction in iPTH Compared to Baseline Level — 17; 57 participants
Hyperparathyroidism, Secondary
Primary: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase — 8.3; 74.0 percentage of participants — p=<0.001
Chronic Kidney Disease on Hemodialysis · Secondary Hyperparathyroidism
Primary: Percentage of Subjects With ≥ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level — 53.3; 41.9; 38.7; 56.7 Percentage of participants
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events — 2; 1; 1; 1 participants
Moderate to Severe Secondary Hyperparathyroidism · Stage 5 Chronic Kidney Diseases
Primary: Mean Erythropoietin Dose Per Visit — 35.8; 22.2; 22.7; 4.7 µg
End-Stage Renal Disease
Primary: Change in Monocyte VDR Expression With Vitamin D Therapy — 1899 units on a scale
Hyperparathyroidism, Secondary
Primary: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase — 9.6; 75.3 percentage of participants — p=< 0.001
Chronic Kidney Failure · Secondary Hyperparathyroidism
Primary: Safety Evaluation of Paricalcitol by Recording the Number of Hospitalizations — 152; 85; 59; 16 participants
Secondary Hyperparathyroidism
Primary: The Percentage of Participants Who Reached a Target Level of Intact Parathyroid Hormone (iPTH) (150-300 pg/mL) Post-baseline at Least Once During the Study — 60.5…
Secondary Hyperparathyroidism
Primary: Number of Participants With iPTH Levels Maintained at the Target Levels of 60-180 pg/mL iPTH Level — 10; 4; 2; 7 participants — p=0.036
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events (AEs) — 354; 337; 108; 799 participants
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Vitamin D Deficiency
Primary: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline — 5; 49…
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Vitamin D Deficiency
Primary: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values — 6; 46…
Chronic Kidney Disease
Primary: The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone Levels — 93; 57; 12; 45 participants